옵션 체인은 다양한 행사가격과 만기일에 대한 Ontrak의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Ontrak에 대한 시장 심리를 평가합니다..

Ontrak (NASDAQ:OTRK) 주식, 옵션 체인

Ontrak

Ontrak Inc is an artificial intelligence (AI)-powered and technology-enabled behavioral healthcare company, whose mission is to help improve the health and save the lives of as many people as possible. The Company's technology-enabled platform utilizes claim-based analytics and predictive modeling to provide analytic insights throughout the delivery of our personalized care program. The company's integrated, technology-enabled OntrakTM solutions, a component of the PRE platform, are designed to treat members with behavioral conditions that cause chronic medical conditions such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure.

Earnings

News

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

ITCI

OTRK

수요일 오전 미국 주식 선물이 상승하면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다: Benzinga Pro의 데이터에 따르면 월스트리트는 애벗 래버러토리스(NYSE:ABT)가 개장 전에 98억 8천만 달러의 매출과 주당 95센트의 분기 수익을 보고할 것으로 예상하고 있다. 애벗 주식은 시간 외 거래에서 1% 상승한 110.30달러를 기록했다.

애벗 래버러토리스, U.S. 뱅코프 및 수요일에 주목해야 할 3가지 주식

Ontrak Inc

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) with a Buy and raises the price target from $8 to $11.

Price Target

Analyst Ratings

CDXC

HC Wainwright & Co. Maintains Buy on ChromaDex, Raises Price Target to $11

The United States is considering a potential partnership with the Democratic Republic of Congo (DRC) to secure access to <a target="_blank" href="https://www.benzinga.com/markets/commodities" rel="noreferrer noopener">critical minerals</a>, following discussions initiated by a senior Congolese official.
According <a target="_blank" href="https://www.ft.com/content/3f638e29-4790-4a10-b5b7-a79f9ef55491" rel="noreferrer noopener">to</a> the Financial Times, the DRC proposed a minerals-for-security deal, offering valuable resources for military support to address ongoing conflict in the region, particularly with the M23 rebel group who seized control of eastern parts of the North Kivu province.
President Felix Tshisekedi recently hinted at the deal in an interview for the New York Times, while a State Department spokesperson confirmed the situation.
"The DRC is endowed with a significant share of the world's critical minerals required for advanced technologies. The United States is open to discussing partnerships in this sector that align with the Trump administration's America First agenda," they said.
The DRC has significant mineral resources, including cobalt, lithium, copper, and tantalum. It is a global leader in cobalt production, supplying over 70% of the metal's production. Cobalt is essential for electric vehicle batteries and renewable energy technologies.
Still, its status has been problematic, as declining prices forced foreign operators like the Chinese miner MMG to <a target="_blank" href="https://www.benzinga.com/news/global/25/03/44168899/mmg-pauses-cobalt-production-in-congo-as-price-hits-historic-lows" rel="noreferrer noopener">pause production</a>. Meanwhile, the government implemented a four-month export ban to stabilize the oversupplied market.
On top of illegal mining and smuggling, escalating armed conflicts are likely the main catalyst for ongoing talks with Washington. The M23 rebel group, allegedly backed by neighboring Rwanda, has seized significant territory in the eastern part of the country, threatening mineral-rich territory.
Since the conflict has also drawn in neighboring Burundi and Uganda, the situation risks escalating into a full-scale regional conflict.
While a deal with the U.S. would stabilize the region, in exchange, the U.S. would gain access to critical minerals and reduce reliance on Chinese-dominated supply chains.
China controls most of the DRC's mining sector through the state-owned MMG. Washington could seize this opportunity to reduce Beijing's influence while securing resources for its industrial needs.
Yet, a deal between Washington and Kinhasa is a tall order. The political climate in Kinshasa is volatile, and past foreign mining agreements in the DRC have faced criticism over transparency issues.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44188315/germany-could-meet-its-lithium-needs-from-domestic-sources-study-says" target="_blank" rel="noreferrer noopener">Germany Could Meet Its Lithium Needs From Domestic Sources, Study Says</a></li>
</ul>
Photo via Shutterstock

Government

Commodities

Politics

BATT

CARZ

DRIV

IDRV

KARS

DR Congo Explores Minerals-For-Security Deal With The US

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) with a Buy and maintains $19 price target.

Reiteration

ALMS

HC Wainwright & Co. Reiterates Buy on Alumis, Maintains $19 Price Target

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) with a Buy and maintains $8 price target.

HC Wainwright & Co. Reiterates Buy on Unity Biotechnology, Maintains $8 Price Target

The acquisition marks a significant step in NETCLASS' strategy to expand its market across Asia. It provides the Company with a new operational center in Tokyo, Japan, and signifies the Company's dedication to its long-term plan through enhancing its software development capability, improving the quality of existing products, and diversifying its customer base

NTCL

NETCLASS TECHNOLOGY Enters Japan Market Via Strategic Acquisition Of Createsolutions; Eyes Regional Growth And Innovation

Today, during TMC's 2025 Annual Meeting &amp; Transportation Technology Exhibition, <a href="https://www.globenewswire.com/Tracker?data=oIBFlhCGj2iyGabzNvH-QtyhXc01zojN8oJuOF7d4khNcCYSVMrKSahqpheVBRVrOBV8ah7WHFnXKLTQJS6ODuT6rH1mclWPco71lhbyDaDAAn69LrrIKnMFs2hsjI20yxrpHrNKmxreMvlYbcPO-oieXFvpAsat3VPHRU7V4jvkIU2qZIMVNJ00iHMDyLADb13xqQhrUWHPtd1ORaAp25AKvE6YIxr4dbbyGx9Qtc5sUtkwcYPFVC-cgVwlPNLwPpINCtaUct3ZJtImL0Or0zzr8hVBjtLYfjHaWM0Nx8R2x5wLpDul2ePtqXN2uFZYAutho7AHfx5vGat2_46S1Ae3YYgRTa2jqdqqDNZvhhq2p35254qxfc2DE211stlDK4XRRD0kWV3DWbhnNaDLEw==">Dragonfly Energy Holdings Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) ("Dragonfly Energy" or the "Company"), an industry leader in energy storage and battery technology, unveiled the new Battle Born&#xAE; DualFlow Power Pack. This innovative lithium power system is designed to eliminate idle time and alleviate strain on starter batteries by providing dedicated power for hotel loads in long haul trucks. Engineered for universal compatibility, the DualFlow Power Pack installs inside the sleeper cab under the bunk without any modifications to existing systems.
The DualFlow Power Pack powers auxiliary loads while the truck is parked by removing cycles from the starter batteries and extending the lifespan while reducing unnecessary engine starts. Once the truck is back in motion, it recharges using Wakespeed&#xAE; Charge Control Technology, making use of available energy without additional fuel consumption. Designed for Heavy-Duty Trucking fleets and owner-operators with sleeper cabs, it is particularly well-suited for fleets that do not use auxiliary air conditioners. With a low price point and an ROI well under a year, the Company believes fleets can quickly recover their investment and witness significant real-world savings in fuel costs, battery replacements, and maintenance.

DFLI

Dragonfly Energy Unveils DualFlow Power Pack to Cut Truck Idle Time, Save Fuel

This is inclusive of non-recurring first-of-a-kind, Project Permian site-specific and owner costs. Provided the successful value engineering process, the project would come online no earlier than 2029.

NPWR

Net Power Now Estimates Project Permian's Total Installed Cost To Be Between $1.7B And $2.0B

Citigroup analyst Spiro Dounis upgrades Pembina Pipeline (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PPL#TSX">PPL</a>) from Neutral to Buy and announces C$63 price target.

Upgrades

TSX:PPL

Citigroup Upgrades Pembina Pipeline to Buy, Announces C$63 Price Target

CYTK

Cytokinetics Said Maintain Expectation For Differentiated Label & Risk Mitigation Profile For Aficamten, If Approved By FDA

<ul>
<li>ARO-C3 achieved deep and sustained reductions in alternative pathway complement activity and proteinuria.</li>
<li>Mean sustained reductions in C3 of ≥87%, AH50 of ≥76%, Wieslab AP of ≥89% through week 24.</li>
<li>Mean reduction in spot urine protein-to-creatinine ratio (UPCR) of 41% by week 24</li>
</ul>

Biotech

Health Care

General

ARWR

Arrowhead Pharmaceuticals Announced Topline Results From Part 2 Of A Phase 1/2 Study Of ARO-C3 To Reduce Liver Production Of Complement Component 3 As A Potential Therapy For Various Complement Mediated Diseases

Management

OPRX

OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer, Effective Mar. 10

<a href="https://www.globenewswire.com/Tracker?data=R6VVCCZIhiwgUK0Su5g-03QsiEEun8cdd7B68fBQab3f-o8XagXSGpWRxYbe3KXmnxg4V22ck5WnzOKfP9JaPJm6lt1rWMx8tCLg6zAAzG4=">Plus Therapeutics</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) (the "Company" or "Plus Therapeutics"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that on March 7, 2025 the Company received confirmation from Nasdaq that the Company has regained compliance with Nasdaq's minimum stockholders' equity requirement. The Company's common stock will continue to be listed and traded on The Nasdaq Capital Market.

Regulations

PSTV

Plus Therapeutics Regains Nasdaq Compliance, Keeps Stock Listed on Capital Market

BEKE

KE Holdings Class A Ordinary Shares Traded On Hong Kong Stock Exchange Have Been Included In Hong Kong Stock Connect And Shenzhen-Hong Kong Stock Connect Programs

Net Power Says It Closed 2024 With $533M In Cash, Cash Equivalents, And Investments, Down From $580M Last Quarter

Genie Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNE#NYSE">GNE</a>) reported quarterly earnings of $0.24 per share. This is a 35.14 percent decrease over earnings of $0.37 per share from the same period last year. The company reported $102.90 million in sales this quarter. This is a 1.91 percent decrease over sales of $104.90 million the same period last year.

Genie Energy Q4 2024 GAAP EPS $0.24 Down From $0.37 YoY, Sales $102.90M Down From $104.90M YoY

Dividends

Buybacks

AMAT

Applied Materials Announces $10B Share Repurchase Authorization And Raises Dividend From $0.40 To $0.46/Share

On Friday, March 7th, U.S. markets closed higher after rebounding from early losses, following remarks by Federal Reserve Chair Jerome Powell that the economy remains &#8220;in a good place.&#8221; However, he cautioned against expecting rapid interest rate cuts, emphasizing a cautious approach.
Despite the late-week rally, persistent uncertainty over U.S. trade policy—especially concerning tariffs on imports from Canada, Mexico, and China—contributed to the S&amp;P 500&#8217;s recording its worst weekly performance since September.
In economic data, February&#8217;s jobs report showed the U.S. added 151,000 jobs—up from January but below the 160,000 forecast. The unemployment rate unexpectedly rose to 4.1%, slightly above the 4.0% estimate.
Most S&amp;P 500 sectors rose Friday, led by utilities, tech, and energy, while consumer staples and financials declined.
The Dow Jones Industrial Average rose 0.54% to close at 42,801.72, the S&amp;P 500 gained 0.55% to 5,770.20, and the Nasdaq Composite was up 0.70% to 18,196.22.
Asia Markets Today
<ul>
<li>On Monday, Japan&#8217;s Nikkei 225 gained 0.34% to 36,990.00, led by gains in the Power, Rubber and Chemical, Petroleum &amp; Plastic sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 rose 0.18%, closing at 7,962.30, led by gains in the Energy, Gold and Resources sectors.</li>
<li>India&#8217;s Nifty 50 was down 0.49% to 22,441.10, while the Nifty 500 slipped 1.02% to 20,234.80.</li>
<li>China&#8217;s Shanghai Composite declined 0.19% to 3,366.16, and the Shanghai Shenzhen CSI 300 fell 0.39% to 3,928.80.</li>
<li>Hong Kong&#8217;s Hang Seng fell 1.85%, ending the session at 23,783.49.</li>
</ul>
Eurozone at 06:00 AM ET
<ul>
<li>The European STOXX 50 was down 0.70%.</li>
<li>Germany&#8217;s DAX declined 0.71%.</li>
<li>France&#8217;s CAC fell 0.39%.</li>
<li>U.K.&#8217;s FTSE 100 index traded lower by 0.40%</li>
</ul>
Commodities at 06:00 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 0.27% at $67.22/bbl, and Brent was up 0.28% at $70.57/bbl.</li>
<li>Oil prices steadied Monday amid tariff uncertainty, rising OPEC+ output, and weak global demand. WTI marked its seventh weekly loss, while Brent fell for a third straight week.</li>
<li>Natural Gas gained 4.35% to $4.588.</li>
<li>Gold was trading higher by 0.06% at $2,915.81, Silver was up 0.64% to $33.020, and Copper slipped 0.62% to $4.6805.</li>
</ul>
U.S. Futures at 06:00 AM ET
<ul>
<li>Dow futures were down 0.80%, S&amp;P 500 futures fell 1.00% and Nasdaq 100 futures slid 1.15%.</li>
<li>U.S. stock futures fell Monday amid tariff uncertainty, recession fears, and weak Chinese inflation data.</li>
</ul>
Forex at 06:00 AM ET
The U.S. Dollar Index slipped 0.14% to 103.70, USD/JPY was down 0.64% to 147.08, and USD/AUD declined 0.30% to 1.5811.
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Market Mixed, Europe Dips; US Futures Slide On Slowdown Fears - Global Markets Today While US Slept

RKT: -10% &#x7C; <a href="https://www.benzinga.com//node/44215917">Rocket Companies shares are trading lower after the company announced it will acquire Redfin in an all-stock transaction valued at $12.50 per share.</a>
&nbsp;
MLYS: 34% &#x7C; <a href="https://www.benzinga.com//node/44215943">Mineralys Therapeutics shares are trading higher after the company reported topline data from its pivotal LAUNCH-HTN Phase 3 and ADVANCE-HTN Phase 2 trials of Lorundrostat for hypertension. Both trials met the primary endpoint.</a>
&nbsp;
TRVI: 41% &#x7C; <a href="https://www.benzinga.com//node/44215929">Trevi Therapeutics shares are trading higher after the company reported topline results from its Phase 2a RIVER trial of Haduvio for RCC, which met the primary endpoint.</a>

Movers

MLYS

TRVI

Market-Moving News for March 10th

U.S. stock futures declined on Monday after a small bout of relief on Friday as indices neared the correction zone. Futures of all four benchmark indices fell in premarket trading.
President Donald Trump, on Sunday, did not rule out the possibility of a recession this year. Acknowledging the potential of short-term turbulence from his economic agenda, he expressed confidence in future prosperity. In a Fox News interview, he said, &#8220;I hate to predict things like that&#8221; and called the changes being brought about by his administration as &#8220;very big.&#8221;
Meanwhile, China responded with retaliatory tariffs on U.S. agricultural goods including its largest import from the U.S. — Soybeans.
Investors will watch out for the inflation data slated to be released this week on Wednesday.
Meanwhile, the 10-year Treasury yield stood at 4.24%, while the two-year yield was at 3.94%. According to the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, there is a 97% chance that the Federal Reserve will keep interest rates unchanged for the March meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-1.22%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.15%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.95%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.04%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Monday. SPY lost 1.03% to fall at $570.00 level, and QQQ declined 1.12% to $486.26, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Utilities, information technology, and energy sectors led Friday&#8217;s U.S. <a href="https://www.benzinga.com/news/earnings/25/03/44212927/dow-gains-over-200-points-but-records-weekly-loss-fear-among-investors-eases-but-greed-index-remains-in-extreme-fear-zone">stock gains</a>, pushing the Dow Jones over 200 points higher. However, consumer staples and financials declined, countering the broader market&#8217;s positive trend. 
Despite Friday&#8217;s rally, all major indices recorded weekly losses: the S&amp;P 500 fell 3.1%, its worst week since September, the Dow dropped 2.4%, and the Nasdaq tumbled 3.5%. Last week, Nasdaq 100 entered the correction territory on Friday, falling nearly 10% from its last high, which eased to 9.1% after Friday&#8217;s sessions, whereas the S&amp;P 500 was 6.1% lower from its last record.
Economic data revealed a mixed picture, with February&#8217;s jobs report showing a moderate increase of 151,000 jobs, below expectations, and a surprise rise in the unemployment rate to 4.1%.
In company news, Genesco Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCO#NYSE">GCO</a>) shares plummeted over 16% on disappointing earnings, while American Public Education Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) shares surged 22% on strong results.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.70%</td>
<td>18,196.22</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.55%</td>
<td>5,770.20</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.52%</td>
<td>42,801.72 </td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.43%</td>
<td>2,075.48</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
According to the Yardeni Research&#8217;s QuickTakes by Ed Yardeni and Eric Wallerstein, &#8220;Anything is possible in Trump World.&#8221;
&#8220;We can&#8217;t rule out the possibility that a bear market started on Feb. 20, the day after the S&amp;P 500 rose to a record high. It could be like the &#8216;flash crashes&#8217; that occurred during 1962 and 1987. It could happen quickly and reverse just as quickly. So the selloff could provide buying opportunities, especially in overvalued names that are now less so,&#8221; the note stated.
According to the note, Trump administration&#8217;s rapid-fire policy initiatives are stress-testing the economy, which has been remarkably resilient so far, and raising fears of a recession.
The current bull market, which began in October 2022, has entered its third year. According to Ryan Detrick, the chief market strategist at Carson Research, it is normal to see some fluctuations in the third year of a bull market.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Not all bull markets make it to their third year, but when they do it is perfectly normal to see some chop and frustration. <a href="https://t.co/moLsIkXAhS">pic.twitter.com/moLsIkXAhS</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1898930376824803647?ref_src=twsrc%5Etfw">March 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
While the conflict around tariffs has raised the speculation of a slowdown and recession, Louis Navellier of Navellier &amp; Associates had a contrarian view. According to him, &#8220;The anxiety over tariffs may be holding back some consumers, but I want to assure you that I do not expect most tariffs to be inflationary. As an example, the tariffs that have been imposed on China are expected to be suppressed by Chinese deflation as well as a weak Chinese yuan.&#8221;
See Also:<a href="https://www.benzinga.com/money/how-to-trade-futures"> How to Trade Futures</a>
Upcoming Economic Data
Here&#8217;s what investors will keep on this week:
<ul>
<li>No data is scheduled to be released on Monday.</li>
</ul>
<ul>
<li>On Tuesday, February&#8217;s NFIB optimism index data will be released at 6:00 a.m., ET.</li>
</ul>
<ul>
<li>January&#8217;s job openings data will be out by 10:00 a.m., ET.</li>
</ul>
<ul>
<li>On Wednesday, February&#8217;s core and headline consumer price index data will be out by 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Monthly U.S. federal budget data for February will be announced at 2:00 p.m., ET.</li>
</ul>
<ul>
<li>On Thursday, the initial jobless claims data for the week ended March 8 will be released at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>The core and headline producer price index data for February will also be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>On Friday, the preliminary consumer sentiment data for March will be released by 10:00 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>BioNTech SE ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) slipped 1.06% in premarket on Monday ahead of its earnings, which will be released before the opening bell. Analysts expect it to report earnings of 58 cents per share on revenue of $1.15 billion.</li>
</ul>
<ul>
<li>Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) dropped 1.44% as Wall Street expects it to report quarterly earnings of $1.49 per share and revenue of $14.40 billion after the closing bell.</li>
</ul>
<ul>
<li>Mission Produce Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVO#NASDAQ">AVO</a>) was down 0.33% ahead of its earnings, which will be released after the closing bell. Analysts expect it to report earnings of 3 cents per share on revenue of $285.50 million.</li>
</ul>
<ul>
<li>Vail Resorts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) was flat at -0.01% as Wall Street expects it to report quarterly earnings of $6.31 per share on revenue of $1.14 billion after the closing bell.</li>
</ul>
<ul>
<li>Cognizant Technology Solutions Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>) jumped by 3.33% following a report on Friday suggesting activist investor, Mantle Ridge, built a more than $1 billion stake in the company.</li>
</ul>
<ul>
<li>Taiwan Semiconductor Mfg. Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) declined 1.41% despite posting a year-on-year rise in its February 2025 revenue. The sales fell on a monthly basis from January by 11.3%.</li>
</ul>
<ul>
<li>Checkpoint Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CKPT#NASDAQ">CKPT</a>) surged 66.40% after Sun Pharma acquired the company for up to $355 million, securing FDA-approved cancer drug UNLOXCYT.</li>
</ul>
<ul>
<li>Sharps Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) zoomed 62.15% after providing business updates. The company raised $20 million, cleared its debt and expanded in Hungary. Also signed a five-year, $50 million syringe deal with a U.S. supplier, which is set to begin revenue generation in the second half of 2025.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.04% to hover around $67.02 per barrel.
The gold spot index was up by 0.28% to $2,903.10 per ounce. Its last record high was at $2,956.37 per ounce. The Dollar Index was down 0.20% at the 103.628 level.
Asian markets closed mixed on Monday as Australia's ASX 200, Japan's Nikkei 225, and South Korea's Kospi index advanced, whereas China's CSI 300, and Hong Kong's Hang Seng index declined. European markets were lower in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44214169/mark-zuckerbergs-meta-platforms-a-lucrative-bet-as-investors-favor-less-leveraged-tech-stocks-says-expert-amid-mag7s-2025-underperformance">Mark Zuckerberg&#8217;s Meta Platforms A Lucrative Bet As &#8216;Investors Favor Less Leveraged Tech Stocks,&#8217; Says Expert Amid Mag7&#8217;s 2025 Underperformance</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Market Summary

Economics

APEI

BNTX

CKPT

CTSH

ORCL

STSS

US Stocks Likely To Open Lower After Trump Hints At Looming Recession: Expert Says Can't Rule Out A Bear Market As Indices Inch Towards Correction Territory

Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a patent by the Korean Intellectual Property Office (KIPO), South Korea's official patent and intellectual property authority. The patent covers the Company's innovative combination therapy of MEAI and N-Acylethanolamines for the treatment of cocaine addiction.
The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center at Bar-Ilan University in Israel. These studies build upon earlier experiments in which animals treated with MEAI exhibited a significant reduction in cocaine-induced cravings.
Further research was conducted in rats to assess whether MEAI's effects on drug-seeking behavior extended to natural rewards, given that reward-based reinforcement is a fundamental survival mechanism across species. The study produced positive results, demonstrating that while MEAI reduced cocaine-seeking behavior, it did not impair the rats' response to natural rewards such as sucrose. This finding suggests that MEAI's impact on drug cravings is not tied to the general reward system but is specifically targeted at drug-related compulsions.
This pioneering research has led to multiple patent applications in the U.S. and other global jurisdictions and is part of Clearmind's ongoing collaboration with SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>) ("SciSparc"), a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders. The collaboration aims to combine Clearmind's MEAI, a novel proprietary psychedelic treatment for addiction and mental health, with SciSparc's PEA

CMND

SPRC

Clearmind Wins South Korea Patent for Psychedelic Therapy Targeting Cocaine Addiction

Press Releases

Ontrak Health Demonstrates Significant Improvement in Members' Quality of Life from ReQoL Mental Health Assessment

Ontrak, Inc. Announces Reverse Stock Split

"Peraso Inc. (NASDAQ: PSRO) Pioneers mmWave Technology: The Next-Generation Wireless Communications" see bonus stocks inside…..

Ontrak Health Collaborates with Major Northeast Regional Plan to Bridge HEDIS Care Gaps Using Ontrak Quality Solution

Ontrak Health to Report 2024 Third Quarter Financial Results on November 13, 2024

Ontrak Health Expands Behavioral Health Solutions with Sentara Health Plans for Commercial and Marketplace Populations

Ontrak Health Announces 2024 Third Quarter Financial Results

Ontrak Health Announces New Customer Partnership with Intermountain Health to Deliver Value-Based Behavioral Health Services to Medicare Advantage Members

Ontrak Health and Sentara Health Plans Execute Three-year Contract Extension Following Several Expansions

Ontrak Health Announces Launch of WholeHealth+ Solution for Intermountain Health

BPTH

LASE

PSRO

American Shared Hospital Services Common Stock

American Shared Hospital

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Kindly MD

23andMe Holding

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

SHL Telemedicine Ltd - American Depositary Shares

SHL Telemedicine

Syra Health

Vivos Therapeutics

Roth MKM

Comments

Ontrak

Ontrak (OTRK) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌